Homotropic cooperativity of monomeric cytochrome P450 3A4 in a nanoscale native bilayer environment

2004 ◽  
Vol 430 (2) ◽  
pp. 218-228 ◽  
Author(s):  
Bradley J. Baas ◽  
Ilia G. Denisov ◽  
Stephen G. Sligar
Keyword(s):  
Cytochrome P450 ◽  
Cytochrome P450 3A4

scholarly journals CO Binding Kinetics of Human Cytochrome P450 3A4

1995 ◽  
Vol 270 (10) ◽  
pp. 5014-5018 ◽  
Author(s):  
Aditya P. Koley ◽  
Jeroen T. M. Buters ◽  
Richard C. Robinson ◽  
Allen Markowitz ◽  
Fred K. Friedman
Keyword(s):  
Cytochrome P450 ◽  
Binding Kinetics ◽  
Cytochrome P450 3A4 ◽  
Human Cytochrome ◽  
Kinetics Of

scholarly journals Severe Adverse Drug Reactions to Quetiapine in Two Patients Carrying CYP2D6*4 Variants: A Case Report

2021 ◽  
Vol 22 (12) ◽  
pp. 6480
Author(s):  
Céline K. Stäuble ◽  
Markus L. Lampert ◽  
Thorsten Mikoteit ◽  
Martin Hatzinger ◽  
Kurt E. Hersberger ◽  
...  
Keyword(s):  
Cytochrome P450 ◽  
Case Report ◽  
Adverse Drug Reactions ◽  
Active Metabolite ◽  
Hepatic Metabolism ◽  
Cytochrome P450 3A4 ◽  
Drug Reactions ◽  
Drug Induced ◽  
Potential Impact ◽  
Intermediate Metabolizer

We report two cases of patients who developed severe adverse drug reactions including persistent movement disorders, nausea, and vertigo during treatment with quetiapine at maximum daily doses ranging between 300 and 400 mg. The extensive hepatic metabolism of quetiapine is mainly attributed to cytochrome P450 3A4 (CYP3A4). However, there is recent evidence supporting the idea of CYP2D6 playing a role in the clearance of the quetiapine active metabolite norquetiapine. Interestingly, both patients we are reporting of are carriers of the CYP2D6*4 variant, predicting an intermediate metabolizer phenotype. Additionally, co-medication with a known CYP2D6 inhibitor and renal impairment might have further affected quetiapine pharmacokinetics. The herein reported cases could spark a discussion on the potential impact of a patient’s pharmacogenetic predisposition in the treatment with quetiapine. However, further studies are warranted to promote the adoption of pharmacogenetic testing for the prevention of drug-induced toxicities associated with quetiapine.

scholarly journals Design of New Schiff-Base Copper(II) Complexes: Synthesis, Crystal Structures, DFT Study, and Binding Potency toward Cytochrome P450 3A4

ACS Omega ◽  
2021 ◽  
Author(s):  
Tunde L. Yusuf ◽  
Segun D. Oladipo ◽  
Sizwe Zamisa ◽  
Hezekiel M. Kumalo ◽  
Isiaka A. Lawal ◽  
...  
Keyword(s):  
Cytochrome P450 ◽  
Schiff Base ◽  
Crystal Structures ◽  
Dft Study ◽  
Cytochrome P450 3A4

Interaction of methadone with substrates of human hepatic cytochrome P450 3A4

Toxicology ◽  
1997 ◽  
Vol 117 (1) ◽  
pp. 13-23 ◽  
Author(s):  
C. Iribarne ◽  
Y. Dréano ◽  
L.G. Bardou ◽  
J.F. Ménez ◽  
F. Berthou
Keyword(s):  
Cytochrome P450 ◽  
Cytochrome P450 3A4 ◽  
Hepatic Cytochrome

scholarly journals Mixing apples and oranges: Analysis of heterotropic cooperativity in cytochrome P450 3A4

2009 ◽  
Vol 488 (2) ◽  
pp. 146-152 ◽  
Author(s):  
Daniel J. Frank ◽  
Ilia G. Denisov ◽  
Stephen G. Sligar
Keyword(s):  
Cytochrome P450 ◽  
Cytochrome P450 3A4
Sign in / Sign up

Export Citation Format

Share Document